Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia

Molecular Medicine Reports
Shiyong ZhouHuilai Zhang

Abstract

Acute myeloid leukemia (AML) is a frequently occurring malignant disease of the blood and may result from a variety of genetic disorders. The present study aimed to identify the underlying mechanisms associated with the therapeutic effects of decitabine and cytarabine on AML, using microarray analysis. The microarray datasets GSE40442 and GSE40870 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) and differentially methylated sites were identified in AML cells treated with decitabine compared with those treated with cytarabine via the Linear Models for Microarray Data package, following data pre‑processing. Gene Ontology (GO) analysis of DEGs was performed using the Database for Annotation, Visualization and Integrated Analysis Discovery. Genes corresponding to the differentially methylated sites were obtained using the annotation package of the methylation microarray platform. The overlapping genes were identified, which exhibited the opposite variation trend between gene expression and DNA methylation. Important transcription factor (TF)‑gene pairs were screened out, and a regulated network subsequently constructed. A total of 190 DEGs and 540 differentially methylated sites were...Continue Reading

References

Mar 27, 2001·Nature Reviews. Genetics·K D Robertson, A P Wolffe
Jun 5, 2002·Genome Research·W James KentDavid Haussler
Feb 13, 2004·Bioinformatics·Laurent GautierRafael A Irizarry
May 28, 2004·Nature·Gerda EggerPeter A Jones
Sep 2, 2005·Nature Reviews. Genetics·Keith D Robertson
May 2, 2006·Statistical Applications in Genetics and Molecular Biology·Gordon K Smyth
May 25, 2007·Nature·Andrew P Feinberg
Jan 15, 2010·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Michael DaskalakisBjörn Hackanson
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Sep 28, 2012·Current Opinion in Oncology·Gail J Roboz
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Aug 8, 2013·Experimental Hematology & Oncology·Richard L Momparler
Aug 1, 2014·The Lancet Oncology·Sara C Meyer, Ross L Levine
Aug 20, 2014·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Ian C G WeaverMichael J Meaney
Feb 20, 2015·Hematology·Eunice S Wang
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Dec 10, 2015·Pediatrics International : Official Journal of the Japan Pediatric Society·Takashi TagaSouichi Adachi
Dec 30, 2015·The Lancet Infectious Diseases·Yongfei HuBaoli Zhu
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T M KadiaH Kantarjian

❮ Previous
Next ❯

Datasets Mentioned

BETA
GSE40442
GSE40870

Software Mentioned

biomaRt
affy
GenomeStudio
Linear Models for Microarray
Illumina Methylation Analyzer
R
Cytoscape

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.